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Abstract
Background Increasingly, the sharing of study results with partici-
pants is advocated as an element of good research practice. Yet lit-
tle is known about how receiving the results of trials may impact
on participants’ perceptions of their original decision to consent.
Objective We explored participants’ views of their decision to con-
sent to a clinical trial after they received results showing adverse
outcomes in some arms of the trial.
Method Semi-structured interviews were conducted with a purpo-
sive sample of 38 women in the UK who participated in a trial of
antibiotics in pregnancy. All had received results from a follow-up
study that reported increased risk of adverse outcomes for children
of participants in some of the trial intervention arms. Data analy-
sis was based on the constant comparative method.
Results Participants’ original decisions to consent to the trial had
been based on hope of personal beneﬁt and assumptions of safety.
On receiving the results, most made sense of their experience in
ways that enabled them to remain content with their decision to
take part. But for some, the results provoked recognition that their
original expectations might have been mistaken or that they had
not understood the implications of their decision to participate.
These participants experienced guilt, a sense of betrayal by the
maternity staﬀ and researchers involved in the trial, and damage
to trust.
Conclusions Sharing of study results is not a wholly benign prac-
tice, and requires careful development of suitable approaches for
further evaluation before widespread adoption.
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Background
Informed consent is the cornerstone of ethical
research practice; providing potential partici-
pants with full information is seen as critical in
promoting autonomous decision making and
preventing exploitation.1 There is extensive evi-
dence, however, that participants’ decisions to
take part in research are often not ‘fully
informed’, but instead are based on trust, altru-
ism and expectations of personal beneﬁt,2–5 and
may involve misunderstandings about study
design.6,7 Although the possibility of decisions
to participate being based on false understand-
ings has received extensive attention,8,9 as,
separately, have participants’ preferences and
expectations for receiving results of studies in
which they have participated10–13 and the emo-
tional impact of receiving those,14,15 little atten-
tion has been given to how people’s views of
the consent they gave on joining a study may be
aﬀected by their learning of the results. This is
an important void given that providing the
results of research to participants is increasingly
framed as an ethical obligation for research-
ers.16,17 In this article, we present empirical
evidence of how receiving the results of a
clinical trial can cause participants to revisit
their decision to take part.
Why do people take part in medical research?
Decisions to participate in medical research are
characteristically founded on the notion of a
co-operative bargain, underpinned by assump-
tions that the values and interests of those
involved in conducting the research are aligned
with participants’ own.5 These assumptions
include expectations that research will contrib-
ute to medical knowledge and improved treat-
ment for future patients, and hence serve the
public good, and that there will be systems for
regulating and monitoring research to ensure
safety – which indeed there are. Participants
also rely heavily on trust; they trust that
research will be conducted in a proper and eth-
ical manner, but they also draw on trust and
conﬁdence in the wider ﬁelds of medicine and
health care, within which they expect to be
protected and cared for.5
This raises the question of what happens
when people receive study ﬁndings that appear
to conﬂict with the expectations that under-
pinned their decision to participate. This is a
particular concern in randomized controlled
trials (RCTs) where the study design means
there is always a risk that outcomes will not be
as good as participants might have hoped.
Randomized controlled trials
RCTs enable systematic investigation of
whether a given treatment confers a beneﬁt for
patients compared with controls – either
another treatment(s) or a placebo. Although
trials are only conducted when there are rea-
sonable grounds to expect beneﬁt from the tri-
alled interventions, and no evidence of harm,
new treatments are found to be better than
existing ones just over half the time, and
new treatments may indeed perform less well.18
Any group that does less well in a situation
speciﬁcally aimed at determining which is the
best intervention may feel disadvantaged –
regardless of whether they are in the control or
intervention group, and in all trials there is the
possibility that some participants will experi-
ence unanticipated adverse outcomes or harm
(Box 1). It is only when participants receive
the results of the trial that they can compare
their outcomes to ‘what could have been’, and
the assumptions and expectations underpinning
their decision to take part may come under
scrutiny.
The Oracle Children’s Study
We use an example of a study that found an
increased risk of adverse outcomes for partici-
pants in the intervention arms of a trial. The
study was a long-term follow-up of children
born to participants in the ORACLE trial, an
RCT that investigated the use of two broad-
spectrum antibiotics for women with suspected
pre-term labour.19,20 The trial was designed to
generate new evidence about the optimal man-
agement of women at risk of pre-term labour.
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The treatment being tested in the trial – antibi-
otics – was a promising intervention for which
there was some prior, but not deﬁnitive, evi-
dence of beneﬁt. The RCT found some beneﬁts
and some risks of antibiotics in the short term.
However, the subsequent long-term follow-up
study – the Oracle Children’s Study – unex-
pectedly found antibiotics to be associated with
increased risks of functioning problems and a
small increased risk of cerebral palsy in chil-
dren whose mothers had had suspected pre-
term labour with intact membranes (SPL), as
well as a small increased risk of bowel prob-
lems in children whose mothers had pre-term
rupture of the membranes (PROM)21,22 (see
Boxes 2 and 3). Extensive work was carried
out to ensure that the return of results was
handled in an appropriate and ethical way, and
procedures were put in place to support women
on receipt of the results (including a national
telephone helpline).23
It is the Oracle Children’s follow-up study
that is our focus of interest. Based on inter-
views with a purposeful sample of women who
elected to receive the results of this study, we
explore how women revisited their decision to
take part in the original ORACLE trial in the
light of receiving the ﬁndings and describe the
emotional sequelae of this
Methods
We conducted semi-structured interviews with
38 women who had participated in the
ORACLE Children’s Study, received the
results of that study in the form of a feedback
leaﬂet (see supplementary material 1) and
responded to an invitation to interview that
accompanied the leaﬂet. Women living within
100 miles of Leicester (UK) were purposively
sampled to ensure diversity in terms of emo-
tional reactions to the leaﬂet (self-reported in a
postal questionnaire) and whether their child
was aﬀected by any of the conditions men-
tioned in the leaﬂet (a functional impairment,
cerebral palsy and/or a bowel problem).
Box 2 The ORACLE trial
The ORACLE trial evaluated the effects of prescribing
erythromycin or co-amoxiclav for women with either
preterm rupture of the membranes (‘waters breaking’
prior to 37 weeks pregnancy) (PROM) or spontaneous
preterm labour with intact membranes (contractions
starting prior to 37 weeks of pregnancy) (SPL), and with
no overt infection, using a 2  2 factorial design.
Findings
For women with PROM
1. Erythromycin was associated with prolongation of
pregnancy and improvements in short-term maternal
and neonatal morbidity; for singletons, there was a
reduction in the composite primary outcome (death
or abnormal cerebral ultrasound or use of
supplemental oxygen at 36 weeks post-menstrual
age).
2. Co-amoxiclav was associated with increased risk of
neonatal necrotizing enterocolitis.
For women with SPL
1. There was no evidence of either benefit or harm at
discharge from hospital.
Box 1 Hypothetical trial and outcomes
Simplified hypothetical trial testing new drug A for
rheumatoid arthritis
Participants are randomized into either an intervention
group, which receives drug A, or a control group which
receives usual care (drug B). The primary outcome is
disability associated with disease progression at one
year following treatment initiation. Possible trial out-
comes include
1. Levels of disability in patients in the intervention
group (drug A) are significantly lower than those in
the control group (drug B) thereby indicating that
trial drug A offers benefit to patients.
2. Levels of disability in patients in the intervention
group (drug A) are not significantly different to those
in the control group (drug B), thereby indicating that
trial drug A offers no benefits over usual care.
3. Levels of disability in patients in the intervention
group (drug A) are not significantly different to
those in the control group (drug B), but a higher
risk of suffering severe migraines is found in the
intervention group. This indicates that trial drug A
offers no benefits over usual care, but is associated
with an increased risk of migraine.
4. Levels of disability in patients in the intervention
group (drug A) are significantly higher than those in
the control group (drug B), thereby indicating that
trial drug A is less effective than usual care.
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Semi-structured interviews were carried out
by CJ, a social scientist trained in qualitative
methods. An interview prompt guide was
developed based on a review of the literature
and project team discussions, and was used
ﬂexibly in interviews. Interviews focused on
participants’ reactions to receiving the study
ﬁndings, and their feelings about having partic-
ipated in the ORACLE trial. Women were not
informed about the trial arm to which they
had been allocated, and nor was the inter-
viewer or any other member of the project
team. Interviews were conducted in partici-
pants’ homes. Each interview lasted approxi-
mately 1 h and was digitally recorded.
Analysis was based on the constant compar-
ative method.24 Initial open coding by SM
informed the development of a thematic coding
framework grounded in the data. The frame-
work was reviewed by the research team and
was used to code all data systematically in
NVivo. Data summaries were produced for
high-level themes. Quotations in the text are
labelled to indicate whether the participant had
PROM or SPL, and whether their child was
aﬀected (A) or not aﬀected (NA) by any of the
conditions mentioned in the Oracle Children’s
Study feedback leaﬂet.
The interview study was given ethics




Thirty-eight women were interviewed, aged
between 28 and 59 years (average age 39). All
but three were of ‘white British’ or ‘white Irish’
ethnicity. Two-thirds (25) had been recruited
into the ORACLE trial due to pre-term rup-
ture of the membranes (PROM), 13 due to
spontaneous pre-term labour (SPL).
At the time of interview, the children born
to participants in the ORACLE trial ranged
from 8 to 13 years old (average 10 years). Six
participants in the interviews reported their
ORACLE child had no health problems; the
children of the remaining 32 had a range of
health problems including cerebral palsy (5),
other neurological problems (6), learning diﬃ-
culties (8), bowel problems (3), respiratory
problems (6), psychological or emotional diﬃ-
culties (9), physical functioning problems (5)
and visual problems (5).
The decision to participate
Women’s accounts of their decisions to consent
to the ORACLE trial of antibiotics demon-
strated that they drew heavily on a hope of
personal beneﬁt and assumptions of safety.
While many women were able to reconcile the
ﬁndings of the follow-up study with their origi-
nal decision to participate, for others the return
of results was disruptive and led them to ques-
tion the basis of their decision to consent to
the trial.
Box 3 The follow-up ORACLE Children Study
The ORACLE Children Study sought follow-up information
for surviving children at 7 years of age in the UK using a
parent-report postal questionnaire. Primary outcome was
defined as the presence of any level of functional
impairment using the Multi-Attribute Health Status
(MAHS) classification system. Secondary outcomes
included a range of medical and behavioural outcomes.
Educational attainment at 7 years was assessed for
children resident in England using results from National
Curriculum tests at Key Stage 1.
Findings
For children whose mothers had PROM
1. There was little evidence of long-term effects of
prescription of antibiotics on the health and
educational attainment of children at 7 years.
For children whose mothers had SPL
1. Prescription of erythromycin was associated with an
increase in the proportions of children with any
level of functional impairment from 38 to 42%.
2. There was an increase in the proportions of children
with cerebral palsy from 1.7 to 3.3% associated
with erythromycin and from 1.9 to 3.2% with
co-amoxiclav.
3. There was a suggestion that more children who
developed cerebral palsy had been born to mothers
who had received both antibiotics in combination.
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Decision making about participation
Women reported that they had been recruited
to the ORACLE trial on arriving in hospital
with premature labour or broken waters. They
were potentially anxious, stressed and in pain.
Despite staﬀ receiving careful training to talk to
women and stress the importance of informed
consent, and women being provided with an
information sheet about the trial approved by
the ethics committee, most of the women in our
study described having made the decision to
take part without much consideration. Their
motivation for participating was primarily a
hope that it might help their baby; women
tended to orient to the trial as an individual
intervention which had the possibility of bring-
ing improved outcomes. This individualistic per-
spective was often coupled with altruistic
motives.
Anything’s a bonus if it’s gonna help then
we’ve got to try it. [. . .] I was hoping and
praying that it would help (Interviewee 16,
PROM, NA)
For me it was important that I participate in the
trial in order to help other women not have to
go through what I went through (Interviewee 37,
SPL, A)
The accounts of women showed that they
had also relied on a heuristic25 about safety – a
mental ‘shortcut’ to facilitate decision making –
that had enabled them to consent to the trial
without having to engage in complex reasoning
at a time when they were feeling anxious and
vulnerable. Women expected, at best, that tak-
ing part in the trial would potentially help their
baby, and at worst, it might make no diﬀerence:
this expectation was strongly reinforced by their
perceptions of antibiotics as a routine and
familiar medication. Although the oﬃcial leaf-
lets approved for the trial explained that there
could be risks associated with taking part,
women described relying on ‘common sense’
understandings of what they were signing up to,
including an implicit assumption that there was
little or no risk involved.26 Only three of the 38
women reported having considered that there
might be negative outcomes: these women
described having explicitly weighed up the risks
of taking part in a trial with the potential for
beneﬁt to their baby. The remainder did not
recall considering the possibility of any risks.
I just remember saying yes straight away. I never
thought about it, so, at the time I never thought
that I was taking a risk. (Interviewee 3, PROM,
A)
Women drew on expectations that the mater-
nity staﬀ caring for them would have their best
interests at heart in inviting them to take part
in the trial. Inherent in the accounts of many
women was the assumption that any risk of
harm would be known about in advance.
You just trust the people that are referring you
through, because no way would they put you
through on a trial knowing that you are preg-
nant with a life and it’s gonna be detrimental to
you and your child. (Interviewee 38, SPL, A)
Further, they drew on wider expectations of
value congruence. They correctly perceived
that those involved in medical research would
be working for the good of patients, would
avoid exposing patients to undue harm and
would only subject them to interventions for
which there was some expectation of beneﬁt
and where risk was expected to be low
(as was the case for the antibiotics in the
trial).
I assumed that they fully expected it to help and
it would I suppose, otherwise I wouldn’t have
said yes. [. . .] You put your trust in the medical
profession and scientists all the time don’t you?
You have to assume that they’re not gonna
deliberately harm you or your child (Interviewee
11, PROM, NA)
For some, their perceptions of the cumula-
tive nature of clinical research, and the strict
controls governing research, provided further
reassurance.
There’s so much regulation and government
guidelines and so on that you’re half way there
to knowing the answers. [. . .] The chances are it’s
not gonna be really harmful (Interviewee 11,
PROM, NA)
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Women’s accounts demonstrated that all
these inferences came together to form a rea-
sonable set of assumptions about safety.
Heuristics about decision to participate
preserved
Despite the negative and potentially distressing
ﬁndings of the Oracle Children’s Study, the
majority of women still valued receiving the
results. It enabled a sense of closure and
completeness, and signiﬁed to women that
the researchers were acknowledging their
contribution.
It was like you’d not been forgotten about really,
that all of us that had done this, we’d done it
and it had been acknowledged by getting the
results. (Interviewee 28, PROM, A)
For the majority of women (around three-
quarters of interviewees), receiving the results
of the follow-up study did not lead them to
question the assumptions and expectations
that they had relied upon in deciding to take
part in the trial; they were able to aﬃrm their
original decision to participate. They acknowl-
edged in hindsight that research involves
uncertainty, and that the negative outcomes
were unlucky and unforeseen. Some argued
that such negative outcomes had to be bal-
anced against the importance of the knowl-
edge and medical advances generated through
research.
I think it’s important to do these things ‘cos it’s
like any trial, if people aren’t willing to partici-
pate then it’s very diﬃcult to move forward. As
hard as that may seem if some people have had
a negative outcome, it’s better to push things for-
ward than always be afraid almost to do any-
thing (Interviewee 12, PROM, NA)
Importantly, although the ﬁnding of nega-
tive outcomes was not what they hoped for,
receiving the results aﬃrmed that the research
had been of value and would beneﬁt other
women in a similar position in the future.
This meant for many women that one of the
core foundations of their decision to take part
– a desire to contribute to the ‘common good’
– remained intact. This enabled women to
continue to feel good about having taken part;
they experienced the warm glow of having
helped others.
Just the thought that something that you’ve done
might help somebody in your position in the
future’s a really good feeling. (Interviewee 10,
PROM, A)
Some women made sense of the results by
re-interpreting them selectively, in ways that
preserved their individual narrative about their
decision to take part in the trial and subse-
quent outcomes for their child. In the feedback
leaﬂet, women were informed that it was not
possible to know whether trial participation
had led to an individual child’s health problems
(and that many children who are born prema-
turely are already at risk from these health
problems); for some women, this information
about uncertainty was helpful. It allowed them
to protect their beliefs that their child had ben-
eﬁtted from the research, or to suspend the
possibility that the research might have harmed
their child. As a result, the expectations that
underpinned their decision to take part in the
trial were preserved, and they were able to
continue feeling that they had done the right
thing.
It’s just that little bit of doubt in my mind - did
[the trial] contribute towards [child’s health prob-
lems . . .]? I just keep an open mind on that. [. . .]
If it does beneﬁt people in future when their
waters go or anything like I think it’s a good
thing really, so I’ve no regrets or anything (Inter-
viewee 13, PROM/SPL, A)
Other women disregarded this information
about uncertainty, and assumed a direct causal
link between trial participation and their own
child’s health outcomes. For some women, this
had positive consequences: although initially
upsetting, it enabled them to make sense of
their child’s health or behaviour, and justify it
to others.
It was pretty tough to get this result, but then
good in a way, that now I know what’s wrong
with him [. . .] and it kind of took a bit of the
pressure oﬀ [child] (Interviewee 9, SPL, A)
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For others, results were seeing as having lit-
tle relevance; these women did not revisit their
decision to take part in the trial, perhaps
because they perceived that they were not in
the ‘at risk’ group, their child did not have
health problems, or they did not fully under-
stand the results.
Did I remember rightly that it reduced [cerebral
palsy] or that it doesn’t aﬀect? [. . .] I think obvi-
ously I was in the other group which is probably
why I didn’t pay [attention] (Interviewee 05,
PROM, A)
Heuristics about decision to participate come
under scrutiny
Although most women came to peace with their
decision to participate in the trial following
receipt of the results, around a quarter of the
women reacted more negatively. These women
experienced a sense of shock at the outcomes of
the research. They were distressed by the dis-
covery that by taking part in the trial they had
exposed their child to a possible risk of harm,
given that their decision to participate was
based on the reasonable assumption that this
would be a safe thing to do. For these women,
receiving the results of the Oracle Children’s
Study led them to call into question the basis
for their decision. This was associated with
extremely negative emotions, including guilt,
anger and a sense of betrayal by the maternity
staﬀ and researchers involved in the trial.
Many of these women’s children had some
form of health problem. Although their child’s
problems could have been caused by multiple
factors, these women found it easy to attri-
bute negative outcomes to trial participation.
Counterfactual thinking – thinking about what
might have been – was a common response.27
This led some women to experience signiﬁcant
feelings of regret and guilt about their decision
to participate in the trial, as they now per-
ceived that it might have been implicated in
harm:
When we saw the potential that he could well
have had the brain damage as a result of the trial
that obviously brings up huge guilt emotion
(Interviewee 08, SPL, A)
These reactions were not limited to women
whose children had been aﬀected by conditions
listed in the leaﬂet giving the results of the
follow-up study. Some women whose children
were not aﬀected by a health problem empa-
thized strongly with others, and felt that,
although they had been lucky, it could have
been their child.
The shock bit about the cerebral [palsy. . .], I was
still part of that and that could have happened
to [child] [. . .] Of course you feel saddened but
you still selﬁshly think ‘but I was okay and this
worked out all right’. (Interviewee 02, SPL, NA)
The women who blamed themselves for
putting their child at risk now regarded the
assumptions they had made, and the heuristics
they had used in making the decision to take
part in the trial as unsound. Receiving the
results of the study exposed to these women
that the bargain they had entered into was not
what they thought it was. They were regretful
or angry that they had relied on assumptions
about beneﬁt and safety, and that they had not
fully understood what they were signing up to.
I felt bad that I’d even done the trial, I thought
by doing what I’d done [. . .] I could have put my
child at risk. (Interviewee 24, SPL, NA)
Others, however, still regarded their assump-
tions as valid. They interpreted the negative
results as a sign that the doctors, nurses or
researchers involved in the trial had failed to
live up to what research participants could
legitimately expect from them, rather than rec-
ognizing that negative results are an unex-
pected but inevitable possibility of any trial.
Although those involved in coordinating the
trial went to great lengths to ensure that
recruitment was conducted in an ethical man-
ner, and the trial did not breach ethical or reg-
ulatory standards in any way, these women
experienced a profound breach of trust. They
questioned the motives and actions of those
involved in the research, feeling that they had
been let down, misled or exploited when they
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were in a distressed and vulnerable position, by
the very nursing and medical staﬀ they trusted
to care for them. They interpreted the negative
outcomes as indicating that the doctors, nurses
or researchers had not fulﬁlled their side of the
co-operative bargain and experienced this as a
sense of betrayal.
I really felt as if I’d been cheated really, and
fooled into taking something that I wouldn’t
have had I have known all the facts [. . .] Angry
for myself for [. . .] trusting that everything was
ﬁne. (Interviewee 31, PROM, NA)
That was my primary concern that, hang on a
minute, I was duped into this by a nurse in a
maternity ward somewhere. (Interviewee 09
SPL, A)
They also questioned the regulatory systems
that they had assumed would prevent this sort
of thing from happening by ensuring drugs
were safe before they were tested on patients.
Just shocked that they could give a drug like that
and not fully know what the reaction would be
to the unborn baby. [. . .] You just wouldn’t think
something they’re giving you would have reper-
cussions, no you think that everything’s been
tested and everything’s been trialled. (Interviewee
09, SPL, A)
Central to the accounts of these women was
a belief that the risks involved could have been
known ‘in advance’ and that only the conspira-
torial, wilfully negligent or malevolent intentions
of researchers could have been responsible for
withholding them from gullible patients. Eight
interviewees said they would deﬁnitely not take
part in a trial again; their experiences had fun-
damentally undermined their trust in research,
and they regretted the risk they felt that they
had unwittingly taken.
I wouldn’t do it, and there’s no way I’d be used
as a guinea pig again [. . .] me and my child.
(Interviewee 31, PROM, NA)
Discussion
Trial outcomes may be concordant with par-
ticipants’ expectations and welcome, but they
also have the potential to be dissonant and
disruptive. Our analysis of sharing the results
of a long-term follow-up of a trial of an inter-
vention in pregnancy found that when study
ﬁndings are not as expected or hoped for,
participants have to ﬁnd ways to make sense
of these outcomes and reconcile them with the
assumptions that underpinned their decision
to take part. In the process, the majority
aﬃrmed their initial assumptions, but some
came to question their decision and the
behaviour and ethics of those involved in the
trial.
Participants in the ORACLE trial accounted
for their decision to participate by describing
expectations of potential for individual beneﬁt,
altruistic motives and a reliance on heuristics
of safety. Women drew on their trust in health
professionals and medicine, and invoked a
vaguely conceptualized regulatory structure, to
underpin their beliefs that they would be pro-
tected from harm. The feeling of safety was
enhanced by the familiarity and low threat
associated with the study intervention (anti-
biotics). When it was unexpectedly found that
antibiotics were associated with risk of harm in
some children, participants had to work to rec-
oncile this unwelcome discovery with their
assumptions and beliefs.
Most were able to rationalize the results in
ways that were consistent with a pre-existing
narrative about their participation and the
subsequent outcomes for their child. For
these women, their assumptions about the co-
operative bargain they had entered into in
agreeing to take part in the research were not
disrupted, and they were able to continue to
feel positive about their experience of taking
part. Yet some participants found it far harder
to reconcile themselves to the ﬁndings. They
responded by internalizing a sense of blame
and experienced regret arising from a belief
that more vigilance on their part when they
consented would have avoided exposure to
risk. Others experienced a sense of betrayal
and undermining of their trust. They concluded
that a lack of vigilance, a lack of concern for
their well-being, or even exploitation or malfea-
sance, on the part of researchers had resulted
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in their being exposed to risk; crucially, they
did not recognize the nature of uncertainty
involved in trials.
In consenting to research, participants
describe drawing heavily on trust ‘borrowed’
from the status of health professionals and
expectations of health care as oﬀering the best
available treatment when needed. However, the
nature of clinical trials means that there is
uncertainty in advance about what that treat-
ment will be. If an intervention performs better
than the control, then those in the control
group may perceive themselves disadvantaged;
the long-term evidence suggests it is almost
equally likely the same eﬀect may occur for
those exposed to unsuccessful trial interven-
tions. Put in the vernacular, those in the least
well-performing arms of a trial may see them-
selves as the ‘losers’. When results are shared
with participants, this discovery of the possibil-
ity of disadvantage can result in participants
experiencing guilt and regret or feelings of
betrayal, and can do damage to trust.8
Although the ORACLE trial had been
designed to meet and exceed ethical and regula-
tory standards, some participants who received
the results came to believe that misconduct
must have occurred and that the research and
professional community had failed to uphold
participants’ trust, rather than recognizing the
negative results as an inevitable potential con-
sequence of trial design. Damage to trust is
particularly problematic for a number of rea-
sons, not least the fact that public trust is criti-
cal to the social licence that enables medical
research to happen.28,29
Although regulations and guidance currently
place a heavy emphasis on the need for partici-
pants to be informed about risk and burdens
when they are recruited to in a trial, in practice
participant information focuses on possible
side-eﬀects of interventions, physical discom-
fort, inconvenience and anxiety during the trial
itself.28,30 Our study suggests that it is equally
important to ensure participants understand
the nature of the bargain they are entering
into, the uncertainties and the risks of negative
outcomes. Novel approaches to the process of
informed consent, such as the use of decision
aids, may be one way of achieving this.31–33
The need for improved training for healthcare
staﬀ to manage the tensions between their roles
as clinicians and as recruiters to research has
also been emphasized.34 Improvements to the
consent process alone, however, are unlikely to
be the full solution, as ideals of informed
consent endorsed by ethical and regulatory
bodies35,36 may be unachievable in practice.30,37
It is important that participants are able to
make decisions that are not based on mistaken
beliefs,37 and likely to be crucial to improving
their ability to do so is greater public under-
standing of the nature of the co-operative
bargain involved in research participation, both
in terms of the science of trials, and the norms
and values that researchers are expected to
adhere to. Despite initiatives to educate and
raise public awareness about research,38–41 and
increased patient involvement in the design and
conduct of trials,42 this is likely to remain chal-
lenging43 and should be a focus of future
eﬀort.
One key implication of our study is the need
for researchers to recognize that there will
always be the potential for the return of results
to cause distress or doubt. Understanding the
basis for reactions such as feelings of guilt and
betrayal may help researchers prepare their
feedback in ways that avoid undermining the
assumptions that underpin decisions to take
part in research: when trial results are not as
hoped for, any feedback to participants should
carefully re-explain nature of clinical trials, and
emphasize that the outcome(s) could not have
been known about nor anticipated in advance.
Further, researchers should anticipate the need
to provide support for participants in the per-
iod following receipt of the results and to con-
sider how damage to trust can be minimized
and repaired. Unblinding participants as to
trial arm allocation needs careful consideration,
as this in itself can have positive and negative
consequences.44 Involving participants in the
design of feedback processes is likely to be
helpful in anticipating and planning for reac-
tions to results.23
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Strengths and limitations
We interviewed a sample of participants purpo-
sively chosen to represent women who experi-
enced a range of emotional reactions to the
results; this enabled us to characterize the diﬀer-
ent ways that participants make sense of their
experience. Participants may not have been rep-
resentative of all the women who participated in
the ORACLE trial, and women whose children
had health and functional problems were proba-
bly been over-represented. It may not be possi-
ble to generalize our ﬁndings to trials where
outcomes are of a diﬀerent nature (e.g. beneﬁt
in the intervention arms of a trial). The women
in our study had participated in a trial during
pregnancy, and results related to their children,
as such, the results may have been particularly
emotive. Trials with more or less at stake, and
with diﬀerent types of intervention (e.g. new
drugs as opposed to familiar medication), may
generate diﬀerent types of response. However,
the underlying dynamics of the co-operative
bargain are likely to be universal.5
The nature of the ORACLE trial meant that
women were recruited to the study when
potentially distressed. This might mean they
were particularly likely to be critical of those
involved in the research. Women were recruited
to the original trial around 10 years ago. This
could have implications for their recall of their
consent decision and introduce potential for
recall bias. Results were sent to women by
post; other means of feeding back results (e.g.
face-to-face) may generate diﬀerent reactions,
and possibly be protective of the social rela-
tionships involved.11
Conclusions
The potential for unexpected negative out-
comes is inherent in any trial, and receiving the
results can lead participants to revisit their con-
sent decision. We found that many participants
remained content with their decision despite
unanticipated negative outcomes, but others
experienced feelings of regret, guilt and a sense
of betrayal. While eﬀorts to ensure that partici-
pants are aware of the nature of the bargain
they are entering into when they consent to a
trial are critical, we may have to accept that
this is not always possible, and that distress
and narrative disruption may be unavoidable
costs of providing feedback to participants.
Sharing of study results appears on the face of
it to be an ethical obligation, but it is not a
wholly benign practice and requires careful
development of suitable approaches for further
evaluation before widespread adoption.
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